Pencoed Business Park
Pencoed CF35 5HY
United Kingdom
44 20 3819 8400
https://www.reneuron.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 26
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Executive Chairman | 430k | N/A | 1954 |
Dr. John David Sinden B.A., BA, M.A., MA, Ph.D. | Co-Founder | 103k | N/A | 1951 |
Ms. Suzanne Hancock | Chief Operations Officer | N/A | N/A | N/A |
Dr. Randolph Corteling Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Mr. Hadley Chilton | Secretary | N/A | N/A | N/A |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
ReNeuron Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.